Quest Diagnostics Inc vs Hasbro, Inc. — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.06B), while Hasbro, Inc. trades at $92.69 (market cap $12.80B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Hasbro, Inc. pays the higher dividend (3.09%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Hasbro, Inc. for 97 Days on average.
| DGX | HAS | |
|---|---|---|
Market Cap | $25.06B | $12.80B |
Volume | 927,361 | 1,356,688 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $105.88 |
52-Week Low | $173.49 | $70.95 |
Typical Hold Time | 56 Days | 97 Days |
Enterprise Value | $30.82B | $14.99B |
Dividend Yield | 1.52% | 3.09% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.03% with consistent earnings beats in recent quarters. The stock shows bearish technical signals despite strong fundamentals including 9.19% net margins and 14.35% ROE. Recent developments include a partnership with Apple Health app and concerns about Medicare reimbursement cuts affecting future revenue streams.
The outlook remains cautiously optimistic with a $250 consensus price target representing 8.3% upside potential. Key opportunities include growth in advanced diagnostics and consumer testing demand, while risks center on Medicare payment reductions and competitive pressures in the diagnostic services market.
Hasbro (HAS) trades at $92.50, up 1.61% today, with a bullish technical outlook and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 20, 2026. Revenue is projected to grow to $5.0B in 2026, with net income rebounding to $794M. The company maintains a solid gross profit margin of 64.41% and positive operating cash flow, though it carries significant long-term debt of $3.38B.
The outlook is positive, driven by earnings momentum and cost-saving initiatives, but risks include high debt levels and competitive pressures. Analyst price targets suggest upside potential, with a consensus target of $107.60. Investors should monitor the upcoming earnings report for confirmation of growth trends and debt management progress.
Trailing returns across standard periods
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →